Journal of Clinical Oncology
Articles in this Issue
Determining lung cancer screening eligibility in a surgically treated urothelial carcinoma population: Making the case for linking bladder cancer screening to lung cancer screening.
875 Background: Bladder cancer is the 10th most common cancer globally, with 573,278 cases reported in 2020. Tobacco consumption is a major risk factor; s...
NSD2 inhibition as a therapeutic approach for treatment-induced neuroendocrine prostate cancer.
198 Background: Trans-differentiation from adenocarcinoma to neuroendocrine histology is a major treatment-induced resistance mechanism against androgen r...
Survival outcomes of testicular cancer (TC) in Hispanic men based on analyses from the National Cancer Database (NCDB).
622 Background: The incidence of TC among Hispanic men has been rising, as reported in our analysis of patients in the United States (Yu et al., JCO 2024...
Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial.
531 Background: L+P significantly improved efficacy vs sunitinib in treatment-naïve pts with aRCC in the CLEAR trial (Motzer 2021). We report data from fu...
A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in metastatic hormone sensitive prostate cancer patients with HRR gene mutation: Updated analysis of PROact.
TPS292 Background: Approximately 10% - 15% of patients with metastatic hormone sensitive prostate cancer (mHSPC) harbor loss-of-function mutations in homo...
Impact of physicians’ awareness of prostate-specific antigen doubling time (PSADT) on treatment (Tx) decisions in high-risk (HR) biochemically recurrent (BCR) prostate cancer (PC).
354 Background: PSADT is one of the strongest predictors of outcomes in patients (pts) with BCR PC and a criterion for HR BCR definition. As such, it is c...
Trends in cardiovascular mortality in older adults with malignant neoplasms of male genital organs in the United States from 1999 to 2020.
29 Background: The American Cancer Society estimated that 1.9 million new cancer cases were identified in 2021, comprising 260,210 newly diagnosed male ge...
Combined analysis of circulating tumor cells and PSMA imaging metrics to predict efficacy of <sup>177</sup> Lu-PSMA-617 in metastatic prostate cancer.
215 Background: Radioligand therapy targeting prostate-specific membrane antigen (PSMA), such as 177 Lu-PSMA-617, has demonstrated...
Assessment of cardiovascular (CV) toxicity by providers in advanced prostate cancer (PCa) patients (pts) on novel hormonal therapy (NHT).
125 Background: Addition of NHT, including Abiraterone, Enzalutamide, Apalutamide, and Darolutamide, to androgen deprivation therapy in patients with adva...
Clinical outcomes for radiographic node-positive prostate cancer following definitive radiotherapy.
352 Background: The incidence of regional lymph node metastases at diagnosis is approximately 15%. Androgen deprivation therapy (ADT) with radiotherapy (R...
Paraneoplastic and symptomatic score for prediction of overall and cancer-specific survival in patients with renal cell carcinoma.
527 Background: Patients presenting with symptomatic renal cell carcinoma (RCC) tend to have more aggressive disease and poorer prognosis. Paraneoplastic...
Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results.
618 Background: Radiation or chemotherapy represent the standard treatment in clinical stage IIA/B seminoma. Despite high cure rates both modalities are a...
Safety evaluation of stereotactic body radiation therapy (SBRT) during lutetium-177-PSMA-617 (177Lu-PSMA-617) treatment for patients with metastatic prostate cancer.
129 Background: Few studies have explored the use of focal therapies to address select sites of resistant disease in men receiving 177-Lu-PSMA-617 for met...
A single-institution experience of pneumonitis in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
475 Background: Immunotherapy (IO) has dramatically changed the treatment landscape for patients with metastatic renal cell carcinoma (mRCC). The expanded...
A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy.
TPS435 Background: Biochemical recurrence (BCR) develops in 20%–50% of patients with prostate cancer (PCa) after initial definitive treatment and is assoc...
Absence of prostate cancer events after 3 years of tailored screening in high-risk individuals with germline pathogenic variants in DNA repair genes.
337 Background: The increasing focus on patient-centered care and the development of precision medicine emphasize the need for alternative screening pathw...
Initial report of a randomized trial of post-prostatectomy prostate cancer radiotherapy using either fluciclovine ( <sup>18</sup> F) or PSMA ( <sup>68</sup> Ga) PET/CT for target dose-escalation.
326 Background: Fluciclovine PET-guided prostate cancer (PCa) radiotherapy (XRT) improves failure-free survival (FFS) over conventional imaging (CI) alone...
Targeting highly aggressive ductal prostate tumours with poly ADP ribose polymerase inhibitor (PARPi) and androgen receptor signaling inhibitor (ARSi) combination therapy.
420 Background: Prostatic ductal adenocarcinoma (DAC) is an aggressive prostate cancer variant, prone to early metastasis at low PSA levels and showing po...
<i>HSD3B1</i> and overall survival (OS) in high-risk non-metastatic (M0) and metastatic (M1) prostate cancer starting androgen deprivation therapy (ADT) in the enzalutamide (ENZ) and abiraterone acetate plus prednisolone (AAP) STAMPEDE phase 3 trial.
234 Background: The HSD3B1 gene encodes for the 3βHSD1 enzyme which regulates the rate-limiting step in potent androgen synthesis...
Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC): A meta-analysis.
128 Background: T-cell engaging bsAbs and CAR T-cell therapy have shown exceptional success in treating multiple hematologic malignancies. More recently,...
Organ perforation and fistula formation as adverse events in patients receiving tyrosine kinase inhibitors: A post-market analysis.
528 Background: Vascular Endothelial Growth Factor (VEGF)-targeted tyrosine kinase inhibitors (TKIs), such as lenvatinib and cabozantinib, offer significa...
Phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patients with muscle invasive bladder cancer ineligible or who refuse cisplatin-based chemotherapy: The PRISMA-1 study.
TPS884 Background: Neoadjuvant cisplatin-based chemotherapy (NACT) has demonstrated a 5-8% improvement in 5-year overall survival (OS) in patients (pts) w...
Docetaxel rechallenge versus cabazitaxel in patients previously treated with docetaxel for metastatic castrate-resistant prostate cancer (mCRPC).
154 Background: In 2004, docetaxel (DOC), a semi-synthetic taxane, received regulatory approval for mCRPC based on improved overall survival (OS). Cabazit...
Efficacy and safety of apalutamide in metastatic castration sensitive prostate cancer patients with a prior history of cardiovascular or metabolic risk factors: A post-hoc analysis of the TITAN study.
165 Background: Patients with CV issues, such as MI, symptomatic congestive heart failure, or thromboembolic events occurring ≤6 months of randomization w...
Cardiovascular mortality risk in primary penile cancer patients: A retrospective cohort study from 2000 to 2021.
7 Background: Primary penile cancer is a rare malignancy, representing less than 1% of all cancers in men in developed countries. The disease predominantl...